Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Enanta Pharmaceuticals ( (ENTA) ).
Enanta Pharmaceuticals announced promising topline results from their Phase 2 pediatric study of zelicapavir, a novel oral treatment for RSV, showing significant antiviral effects and a favorable safety profile. The study involved children aged 28 days to 36 months and demonstrated a notable reduction in viral load, especially in those treated within three days of symptom onset. These results highlight zelicapavir’s potential as an effective treatment for RSV, supporting further clinical evaluation.
Find detailed analytics on ENTA stock on TipRanks’ Stock Analysis page.
